| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
100,577 |
7,640 |
$4.64M |
| A4657 |
Syringe, with or without needle, each |
5,812 |
5,310 |
$2.57M |
| J1270 |
Injection, doxercalciferol, 1 mcg |
36,298 |
3,309 |
$306K |
| 0250 |
|
6,366 |
1,216 |
$282K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
85,932 |
5,240 |
$188K |
| J1756 |
Injection, iron sucrose, 1 mg |
16,997 |
4,685 |
$133K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
1,821 |
1,042 |
$127K |
| 82728 |
|
3,411 |
3,088 |
$48K |
| 85041 |
|
4,888 |
4,397 |
$5K |
| 90674 |
|
120 |
115 |
$5K |
| 90662 |
|
238 |
234 |
$5K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
2,198 |
1,688 |
$3K |
| G0008 |
Administration of influenza virus vaccine |
256 |
251 |
$1K |
| 83970 |
|
3,135 |
2,823 |
$833.48 |
| 83540 |
|
3,625 |
3,238 |
$723.98 |
| 90661 |
|
12 |
12 |
$397.92 |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
468 |
89 |
$194.98 |
| 83550 |
|
3,404 |
3,065 |
$99.40 |
| 85048 |
|
4,813 |
4,328 |
$39.33 |
| 82108 |
|
303 |
242 |
$6.58 |
| 0305 |
|
206 |
91 |
$0.00 |
| 0012A |
|
17 |
15 |
$0.00 |
| 0301 |
|
254 |
66 |
$0.00 |
| 0636 |
|
961 |
72 |
$0.00 |
| 0821 |
|
40 |
37 |
$0.00 |
| 0064A |
|
33 |
33 |
$0.00 |
| 0011A |
|
16 |
14 |
$0.00 |
| 0270 |
|
100 |
89 |
$0.00 |
| 0302 |
|
28 |
17 |
$0.00 |
| 85045 |
|
63 |
55 |
$0.00 |
| 0635 |
|
45 |
13 |
$0.00 |
| 0124A |
|
28 |
28 |
$0.00 |
| 0634 |
|
1,939 |
98 |
$0.00 |